- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04682834
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
October 12, 2023 updated by: Iterum Therapeutics, International Limited
Expanded Access for the Use of Sulopenem Etzadroxil/Probenecid for the Treatment of Patients With Complicated Urinary Tract Infection Due to Quinolone-nonsusceptible Uropathogens
Sulopenem etzadroxil/probenecid is available to clinicians through an Expanded Access Program for the treatment of complicated urinary tract infections due to quinolone nonsusceptible uropathogens after an initial course of effective intravenous therapy.
The investigational product may be requested by sending an email to the Sponsor (EAProgram@iterumtx.com), as listed on the Reagan Udall EAP Navigator website (https://navigator.reaganudall.org/company-directory/i).
Study Overview
Status
Available
Intervention / Treatment
Detailed Description
This Expanded Access Program will allow clinicians to use sulopenem etzadroxil/probenecid for the treatment of patients with serious or immediately life-threatening complicated urinary tract infection due to quinolone-nonsusceptible uropathogens where there are no satisfactory oral alternatives to use as step-down therapy after receiving an initial course of effective intravenous therapy.
The recommended dose of sulopenem etzadroxil/probenecid 500 mg/ 500 mg is one bilayer tablet orally twice daily, taken with food whenever possible.
No dose adjustment is required for patients with renal impairment.
Duration of therapy will be at the discretion of the prescribing clinician, depending on the type of infection being treated and the response to therapy, and is expected to be less than ten days total.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
- Adults ≥18 years of age with complicated urinary tract infection due to a quinolone-nonsusceptible uropathogen
- Patient or the patient's legally acceptable representative able to provide a signed written informed consent prior to any study-specific procedures.
- Clinically documented pyelonephritis or complicated urinary tract infection for which at least one dose of effective intravenous antibiotics has been received.
Exclusion Criteria:
- Patients who require concomitant administration of valproic acid
- Patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs or probenecid.
- Patients with known uric acid kidney stones
- Patients requiring concomitant use of ketorolac tromethamine or ketoprofen
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
December 18, 2020
First Submitted That Met QC Criteria
December 18, 2020
First Posted (Actual)
December 24, 2020
Study Record Updates
Last Update Posted (Actual)
October 13, 2023
Last Update Submitted That Met QC Criteria
October 12, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease Attributes
- Nephritis
- Nephritis, Interstitial
- Pyelitis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Infections
- Communicable Diseases
- Urinary Tract Infections
- Pyelonephritis
- Antirheumatic Agents
- Gout Suppressants
- Uricosuric Agents
- Probenecid
Other Study ID Numbers
- IT001-307
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pyelonephritis
-
Paratek Pharmaceuticals IncCompletedAcute PyelonephritisGeorgia, Latvia, Russian Federation, Ukraine
-
University Hospital, Clermont-FerrandCompletedAcute Uncomplicated PyelonephritisFrance
-
University of Southern DenmarkCompletedAcute PyelonephritisDenmark
-
University of Southern DenmarkCompletedAcute PyelonephritisDenmark
-
Shahid Beheshti UniversityUnknownAcute Pyelonephritis(APN)Iran, Islamic Republic of
-
University of ManitobaJanssen-Ortho Inc., Canada; PriCara, Unit of Ortho-McNeil, Inc.; Ortho-McNeil...TerminatedAcute Uncomplicated PyelonephritisCanada
-
MerLion Pharmaceuticals GmbHCompletedUrinary Tract Infections | Acute PyelonephritisGermany
-
Shahid Beheshti UniversityUnknownAcute Pyelonephritis(APN)Iran, Islamic Republic of
-
University of Southern DenmarkCompleted
-
Institut Investigacio Sanitaria Pere VirgiliHospital Arnau de Vilanova; Fundació Institut de Recerca de l'Hospital de la... and other collaboratorsCompletedAcute PyelonephritisSpain
Clinical Trials on Sulopenem Etzadroxil/Probenecid
-
Iterum Therapeutics, International LimitedCompletedCystitis | Urinary Tract InfectionsUnited States
-
Iterum Therapeutics, International LimitedCompletedUncomplicated Urinary Tract InfectionsUnited States
-
Iterum Therapeutics, International LimitedCompletedComplicated Urinary Tract InfectionsUnited States, Estonia, Hungary, Georgia, Latvia
-
Iterum Therapeutics, International LimitedCompletedIntra Abdominal InfectionsUnited States, Bulgaria, Estonia, Georgia, Hungary, Latvia, Poland
-
University of MiamiUnited States Department of DefenseRecruitingInfertility, MaleUnited States
-
Iterum Therapeutics, International LimitedWithdrawnIntraabdominal Infections | Urinary Tract Infections | Pyelonephritis AcuteUnited States
-
University of Maryland, BaltimoreNational Institutes of Health (NIH); National Institute of General Medical...Completed
-
VA Office of Research and DevelopmentRecruiting
-
TrippBio, Inc.Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States